Login to Your Account

Financings Roundup

Is Tau How? GMS Bets $31.5M on Alzheimer's Phase III Effort

By Randy Osborne
Staff Writer

Tuesday, November 20, 2012
After years of throwing themselves futilely against the beta amyloid wall, companies trying for Alzheimer's disease (AD) therapies are turning away, hoping to find a door that opens on a way to modify the devastating condition.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription